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Abstract: Two decades since the discovery of the RNA interference (RNAi) pathway, we are now
witnessing the approval of the first RNAi-based treatments with small interfering RNA (siRNA) drugs.
Nevertheless, the widespread use of siRNA is limited by various extra- and intracellular barriers,
requiring its encapsulation in a suitable (nanosized) delivery system. On the intracellular level,
the endosomal membrane is a major barrier following endocytosis of siRNA-loaded nanoparticles
in target cells and innovative materials to promote cytosolic siRNA delivery are highly sought
after. We previously identified the endogenous lung surfactant protein B (SP-B) as siRNA delivery
enhancer when reconstituted in (proteo) lipid-coated nanogels. It is known that the surface-active
function of SP-B in the lung is influenced by the lipid composition of the lung surfactant. Here,
we investigated the role of the lipid component on the siRNA delivery-promoting activity of SP-B
proteolipid-coated nanogels in more detail. Our results clearly indicate that SP-B prefers fluid
membranes with cholesterol not exceeding physiological levels. In addition, SP-B retains its activity
in the presence of different classes of anionic lipids. In contrast, comparable fractions of SP-B did not
promote the siRNA delivery potential of DOTAP:DOPE cationic liposomes. Finally, we demonstrate
that the beneficial effect of lung surfactant on siRNA delivery is not limited to lung-related cell types,
providing broader therapeutic opportunities in other tissues as well.
Keywords: siRNA delivery; nanoparticles; pulmonary surfactant
1. Introduction
Over the last two decades, research in the field of RNAi therapeutics has gained attention as
it allows to address diseases at the transcriptome level [1]. Once they reached the cytosol, small
interfering RNAs (siRNAs) activate the RNAi machinery, leading to post-transcriptional gene silencing
through sequence-specific degradation of mRNA [2,3]. High target specificity and versatility of this
emerging class of therapeutics represent some of the main advantages compared to conventional
small molecule drugs and monoclonal antibodies, providing a wide range of biomedical uses [1,3].
However, their application in the clinic is limited by many extra- and intracellular delivery barriers.
Most importantly, negatively charged hydrophilic macromolecules like siRNAs cannot cross biological
membranes, making cellular delivery challenging [1,4].
Viral vectors are often applied carriers to guide cellular delivery of nucleic acids. However,
labor-intensive large-scale production and safety issues remain important drawbacks, hence encouraging
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research for non-viral alternatives [4–6]. Encapsulation of siRNA into synthetic nanoparticles (NPs)
allows its internalization by cells through endocytosis followed by release of the encapsulated RNA
into the cytosol (i.e., endosomal escape). Among the vast number of NPs under investigation, cationic
lipid nanoparticles (LNPs) currently are the preferred material for RNA delivery [7]. To date, many
cationic lipid materials have been synthetized for LNP production [8–13]. However, the endosomal
escape efficiency often remains poor [4,14–16]. Moreover, concerns remain regarding their safety and
immunogenicity [12,17]. As such, to expedite clinical translation of this highly promising class of
therapeutics, lipid-based siRNA formulations are needed to merge efficient cellular delivery with
acceptable toxicity.
As synthetic polymer-and lipid-based NPs often fail to combine biocompatibility and efficacy,
there is a growing interest in using bio-inspired materials [18]. We recently reported on a bio-inspired
nanocomposite, composed of a siRNA-loaded polymeric matrix core surrounded by a shell of clinical
pulmonary surfactant, i.e., poractant α (Curosurf®) (Figure 1) [19].
Pharmaceutics 2019, 11, x 2 of 17 
 
Viral vectors are often applied carriers to guide cellular delivery of nucleic acids. However, 
labor-intensive large-scale production and safety issues remain important drawbacks, hence 
encouraging research for non-viral alternatives [4–6]. Encapsulation of siRNA into synthetic 
nanoparticles (NPs) allows its internalization by cells through endocytosis followed by release of the 
encapsulated RNA into the cytosol (i.e., endosomal escape). Among the vast number of NPs under 
investigation, cationic lipid nanoparticles (LNPs) currently are the preferred material for RNA 
delivery [7]. To date, many cationic lipid materials have been synthetized for LNP production [8–13]. 
However, the endosomal escape efficiency often remains poor [4,14–16]. Moreover, concerns remain 
regarding their safety and immunogenicity [12,17]. As such, to expedite clinical translation of this 
highly promising class of therapeutics, lipid-based siRNA formulations are needed to merge 
efficient cellular delivery with acceptable toxicity. 
As synthetic polymer-and lipid-based NPs often fail to combine biocompatibility and efficacy, 
there is a growing interest in using bio-inspired materials [18]. We recently reported on a 
bio-inspired nanocomposite, composed of a siRNA-loaded polymeric matrix core surrounded by a 
shell of clinical pulmonary surfactant, i.e., poractant α (Curosurf®) (Figure 1) [19]. 
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Pulmonary surfactant (PS) is a surface-active material that is produced and secreted into the 
alveolar space by specialized alveolar type II epithelial cells. PS covers the entire alveolar surface 
and its main physiological role is to maintain low surface tension upon expiration to prevent 
alveolar collapse [20]. Natural human PS has a complex composition of lipids (~90 wt%) and 
proteins (~10 wt%). The lipid fraction mainly contains zwitterionic phosphatidylcholine (PC) 
(~60–70 wt%) as well as anionic phosphatidylglycerol (PG) (~10 wt%) species and neutral lipids, of 
which cholesterol is the most abundant (~8–10 wt%). The protein fraction consists of two major 
classes of specialized surfactant proteins (SPs), i.e., the larger and hydrophilic SP-A and SP-D, as 
well as the smaller hydrophobic SP-B and SP-C [21,22]. PS has been extensively studied mainly 
because of its functional role in mammalian breathing [22,23]. In the context of inhalation therapy 
with nanomedicines, PS is primarily regarded as one of the extracellular barriers in the deep lung 
that needs to be overcome to gain access to underlying target cells upon inhalation therapy [21]. Its 
current therapeutic use is limited to the treatment of respiratory distress syndrome in premature 
infants, where modified PS from animal origin (e.g., Curosurf®) is approved for so-called surfactant 
replacement therapy [23]. 
Unexpectedly, we observed that the PS outer layer in the above mentioned nanocomposites 
significantly enhanced intracellular siRNA delivery in lung epithelial cells and (primary) alveolar 
macrophages [21,24]. Although it constitutes only a minor fraction in PS, surfactant protein B (SP-B) 
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anionic phosphatidylglycer l (PG) (~10 wt%) species and neutral lipids, of which cholesterol is the
most abundant (~8–10 wt%). The protei fraction consists of two major classes of specialized surfactant
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underlying target cells upon inhalation herapy [21]. Its curr nt therapeutic use is limited to the
treatment of respiratory distress syndrome in prema ure infants, where modified PS from animal origin
(e.g., Curosurf®) is approved for so-called surfactant replacement therapy [23].
Unexpectedly, we observed that the PS outer layer in the above mentioned nanocomposites
significantly enhanced intracellular siRNA deliv y in lung epithelial cells and (primary) alveolar
macrophages [21,24]. Although it constitutes only a minor fraction in PS, surfactant protein B (SP-B)
w s identified as a key component for he improved RNA delivery (Figure 1) [25]. The beneficial
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effect of PS and the PS-associated SP-B on RNA delivery is a very recent finding and therefore remains
largely unexplored in the literature. Qiu and colleagues reported on the cationic amphiphilic peptide
KL4, a synthetic SP-B mimic, as siRNA carrier for lung delivery, reaching efficient delivery in vitro [26].
The Anderson group covalently conjugated the truncated cationic domain of SP-B to the surface of
lipidoid NPs to improve siRNA delivery [27].
Hence, many questions remain on this unique function of PS and native SP-B. First, given its
natural origin, proof-of-concept on SP-B promoted siRNA delivery has been limited to lung-related cell
types. Here, we sought to confirm this specific activity of SP-B on other cell types as well. In addition,
our earlier data suggest that the type of lipid with which the SP-B is associated, can influence its siRNA
delivery efficiency. In this report, we therefore investigated the importance of the lipid composition on
the siRNA delivery activity of SP-B in more detail. In particular, the impact of cholesterol, membrane
fluidity and anionic lipid type in the SP-B inspired proteolipid shell of the nanocomposites is probed.
Finally, we sought to reconstitute the cationic amphiphilic SP-B in DOTAP:DOPE cationic liposomes
with the aim to promote their cellular siRNA delivery efficiency.
2. Materials and Methods
2.1. Small Interfering RNAs
Twenty-one nucleotide small interfering RNA (siRNA) duplexes targeting Enhanced Green
Fluorescent Protein (siEGFP), non-targeting negative control duplexes (siCTRL), protein tyrosine
phosphatase receptor type C (siCD45) and pGL3 firefly luciferase (siLuc) were purchased from
Eurogentec (Seraing, Belgium). For cellular uptake experiments, the siCTRL duplex was labeled
with a Cy5® dye at the 5′ end of the sense strand (siCy5). The fluorescent labeling was performed
and verified by Eurogentec. The concentration of the siRNA stock solutions in nuclease-free water
(Ambion®-Life Technologies, Ghent, Belgium) was calculated from absorption measurements at 260 nm
(1 OD260 = 40 µg/mL) with a NanoDrop 2000c UV-Vis spectrophotometer (Waltham, MA, USA).
For siEGFP: sense strand = 5′-CAAGCUGACCCUGAAGUUCtt-3′; antisense strand = 5′-GAACUU
CAGGGUCAGCUUGtt-3′. For siCTRL: sense strand = 5′-UGCGCUACGAUCGACGAUGtt-3′;
antisense strand = 5′-CAUCGUCGAUCGUAGCGCAtt-3′. For siCD45: sense strand = 5′-GAA-GAA-
UGC-UCA-CAG-AUA-A-3′; antisense strand = 5′-UUA-UCU-GUG-AGC-AUU-CUU-C-3′ (capital
letters represent ribonucleotides; lower case letters represent 2′-deoxyribonucleotides). The sequence
of siLuc is confidential and not available to be listed.
2.2. Synthesis of Dextran Nanogels and siRNA Complexation
Dextran hydroxyethyl methacrylate (dex-HEMA) or dextran methacrylate (dex-MA) [18,28–30]
was copolymerized with a cationic methacrylate monomer [2-(methacryloyloxy)ethyl]-trimethyl-
ammonium chloride (TMAEMA) to produce cationic dex-HEMA-co-TMAEMA (degree of substitution
(DS) of 5.2) and dex-MA-co-TMAEMA (DS of 5.9) nanogels (hereafter abbreviated as respectively
dex-HEMA NGs and dex-MA NGs), using an inverse miniemulsion photopolymerization method
as previously reported [24,25,31–33]. The synthetized NGs were lyophilized and stored desiccated
to ensure long term stability. To make siRNA-loaded nanogels (siNGs), 2 mg/mL of NG stock
solutions were prepared by dispersing a weighed amount of the lyophilized nanoparticles in ice-cooled
nuclease-free water, followed by brief sonication (Branson Ultrasonics Digital Sonifier®, Danbury,
CT, USA). To allow siRNA complexation, equal volumes of siRNA and NGs in (4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid) (HEPES) buffer (20 mM, pH 7.4) were mixed and incubated for
≥10 min at 4 ◦C.
2.3. Preparation of Proteolipid-Coated Nanogels
The commercially available clinical lung surfactant derived from minced porcine lungs, Poractant
α (Curosurf®) (Chiesi Pharmaceuticals, Parma, Italy), was used to form the pulmonary surfactant
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(PS) outer layer on siNGs. To prepare the PS-inspired proteolipid coating the following lipids were
used: 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3- phosphocholine
(DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), l-α-phosphatidyl- glycerol from egg yolk
(egg PG), l-α-phosphatidyl-l-serine (soy PS) and l-α-phosphatidylinositol from soy (soy PI). Soy PS
was purchased from Sigma-Aldrich, all other lipids were obtained from Avanti Polar Lipids (Alabaster,
AL, USA). SP-B was isolated from native porcine pulmonary surfactant following a procedure described
earlier by Pérez-Gil and coworkers [34]. The lipids with or without SP-B (0.4 wt%) were mixed at
the required weight ratios in chloroform and a (proteo) lipid film was obtained via nitrogen flow or
rotary evaporation. The resulting lipid film was hydrated using HEPES buffer (20 mM, pH 7.4) and
subsequently mixed with equal volumes of the previously formed siNGs (15 mg lipid/mg nanogel) [25].
The formation of the proteolipid coat was obtained by ≥ 10 min incubation at 4 ◦C and three 10”
cycles of high-energy sonication (amplitude 10%), using a probe sonicator (Branson Ultrasonics Digital
Sonifier®, Danbury, CT, USA). To obtain Curosurf-coated siNGs (CS-NGs), the Curosurf® dispersion
(80 mg/mL) was diluted in HEPES buffer and mixed in equal volumes with the previously formed
siNGs (15 mg lipid/mg nanogel), following an identical incubation and sonication protocol as detailed
above. Hydrodynamic diameter, dispersity (Ð) and ζ-potential of all formulations were measured via
Dynamic Light Scattering (DLS) (Zetasizer Nano, Malvern Instruments, Worcestershire, UK).
2.4. Preparation of Cationic Liposomes
To prepare cationic liposomes, 1,2-dipalmitoyl-3-trimethylammonium-propane (DOTAP) and
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) were purchased from Avanti Polar Lipids
(AL, USA). DOTAP:DOPE liposomes (50:50 molar ratio) were prepared by mixing appropriate amount
of the mentioned lipids in chloroform in a round bottom flask. In the case of DOTAP:DOPE:SP-B
liposomes, 1 wt% of SP-B was added to the lipid mixture in chloroform. A lipid film was obtained
via rotary evaporation and subsequently hydrated with HEPES buffer (20 mM, pH 7.4). The lipid or
lipid-protein dispersion was sonicated using a probe sonicator (Branson Ultrasonics Digital Sonifier®,
Danbury, CT, USA) for 30” via a pulsed program using 10% amplitude. DOTAP:DOPE liposomes
were complexed with siRNA at a charge ratio (nitrogen/phosphate ratio) equal to 8, to obtain the
formation of the so-called lipoplexes (LPX). Hydrodynamic diameter, dispersity (Ð) and ζ-potential
of all formulations were measured via Dynamic Light Scattering (DLS) (Zetasizer Nano, Malvern
Instruments, Worcestershire, UK).
2.5. Cell Lines and Culture Conditions
Cell culture experiments were performed using a human non-small cell lung cancer cell line stably
expressing EGFP (H1299_eGFP) [25], a human ovarian cancer cell line stably expressing luciferase
(SKOV3_LUC) [35], a human hepatoma cell line stably expressing eGFP (Huh-7_eGFP) [36] and a
murine alveolar macrophage cell line (MH-S). The H1299_eGFP and SKOV-3_LUC were respectively
obtained from the lab of Prof. Foged (Department of Pharmacy, University of Copenhagen, Copenhagen,
Denmark) and the lab of Prof. Aigner (Institute of Pharmacology, Pharmacy and Toxicology, University
of Leipzig, Leipzig, Germany). The Huh-7 cell line was obtained from the lab of Prof. Lahoutte, (VUB,
Brussels, Belgium). Huh-7_eGFP were generated by transfecting Huh-7 cells with the pEGFP-N2
plasmid (Clontech, Palo Alto, CA, USA). The MH-S cell line was provided by VIB-UGent. H1299_eGFP
cells were cultured in RPMI 1640, supplemented with 10% fetal bovine serum, 2 mM glutamine and
100 U/mL penicillin/streptomycin. Cells were treated with medium containing 1 mg/mL Geneticin®
once per month. SKOV-3_LUC were cultured in McCoy’s 5A medium, supplemented with 10% FBS
and 100 U/mL penicillin/streptomycin. Huh-7_eGFP cells were cultured in DMEM:F12 supplemented
with 10% fetal bovine serum, 2 mM glutamine and 100 U/mL penicillin/streptomycin. MH-S were
cultured in RPMI 1640 supplemented with 2 mM glutamine, 10% fetal bovine serum, 100 U/mL
penicillin/streptomycin, 10 mM HEPES, 1 mM sodium pyruvate and 0.05 mM 2-mercaptoethanol.
All cells were cultured at 37 ◦C in a humidified atmosphere containing 5% CO2 and were passed
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every 3 days using a 0.25% trypsin-ethylenediaminetetraacetic acid (EDTA) solution to maintain
subconfluency. All cell culture materials were purchased from Gibco®-Life Technologies, except for
the serum, which was delivered by Hyclone™ (Thermo Fisher Scientific, Waltham, MA, USA).
2.6. Quantification of In Vitro Cellular siRNA Uptake by Flow Cytometry
To quantify the cellular internalization of siRNA via flow cytometry, H1299_eGFP cells
(2 × 104 cells/cm2 in 24-well plates), MH-S cells (4 × 104 cells/cm2 in 12-well plates), Huh-7_eGFP cells
(4 × 104 cells/cm2 in 24-well plates) or SKOV-3_LUC cells (1.85 × 104 cells/cm2 in 24-well plates) were
plated (Greiner Bio-One GmbH, Kremsmünster, Austria) and allowed to settle overnight. NGs were
loaded with siCTRL:siCy5 (100:0.75 mol%) and coated with a proteolipid mixture using the procedure
described above. The particles were diluted 5 times in Opti-MEM to a final concentration of 30 µg/mL
and incubated with the cells for 4 h (37 ◦C, 5% CO2). Next, the cells were washed with dextran sulfate
sodium salt (0.1 mg/mL in PBS) to remove cell surface-bound fluorescence prior to flow cytometric
quantification. To quantify uptake percentage, the mean fluorescence intensity (MFI) of cells treated
with coated NGs were normalized to the ones of cells treated with uncoated NGs (representing 100%).
For cationic liposomes, H1299_eGFP cells were seeded in 96-well plates (SPL Lifesciences Co. Ltd.,
Gyeonggi-do, South Korea) at a density of 2 × 104 cells/cm2 and allowed to settle overnight. Liposomes
were used for complexation of a mixture of siCTRL:siCy5 (90:10 mol%), diluted in Opti-MEM, and
incubated with the cells for 4 h (37 ◦C, 5% CO2), followed by flow cytometric analysis as mentioned
above. Data analysis was performed using the FlowJoTM analysis software (Treestar, Costa Mesa,
CA, USA).
2.7. Quantification of eGFP Gene Silencing by Flow Cytometry
To quantify gene knockdown efficiency, H1299_eGFP cells (2 × 104 cells/cm2) or Huh-7_eGFP
(4 × 104 cells/cm2) were plated in 24-well plates (Greiner Bio-One GMBH) and allowed to settle
overnight. Particles were prepared in Opti-MEM as described above and incubated with the cells (4 h
at 37 ◦C and 5% CO2). Next, cells were washed with PBS and incubated with 1 mL fresh cell culture
medium for 48 h. At this point, cells were prepared for flow cytometry as described above and a
minimum of 104 cells were analyzed for each sample. The eGFP expression percentage was calculated
normalizing the MFI of cells treated with siEGFP to the MFI of cells treated with siCTRL. Data analysis
was performed using the FlowJoTM analysis software (Version 10.5.3, Treestar, Costa Mesa, CA, USA,
1997–2018).
2.8. Luciferase Silencing in Human Ovarian Carcinoma Cells
SKOV-3_LUC were seeded in 24-well plates at a density of 1.85 × 104 cells/cm2 and allowed
to attach overnight. Particles were prepared as described above and diluted in Opti-MEM before
incubation with the cells (4 h at 37 ◦C and 5% CO2). Next, cells were washed with PBS and incubated
with 1 mL fresh cell culture medium for 24 h. At this time point, cell culture medium was removed
and the cells were washed with PBS. Subsequently, luminescence was measured using the Luciferase
Reporter Assay Kit, following the optimized Promega protocols and reagents. Luciferase activity of
each sample was assayed in a GloMax™ 96 Luminometer (Promega, Madison, WI, USA).
2.9. Quantification of In Vitro CD45 Silencing in MH-S by Flow Cytometry
MH-S cells were seeded in 12-well plates and allowed to settle overnight. Particles were prepared
as described above and diluted in Opti-MEM (final NG concentration of 30 µg/mL; final siRNA
concentration of 100 nM) before incubation with the cells (4 h at 37 ◦C and 5% CO2). Afterwards,
the cells were washed with PBS and 1 mL of culture medium was added. Forty-eight hours after
transfection, the cells were detached with a non-enzymatic cell dissociation buffer (10 min incubation
at 37 ◦C). After centrifugation (7 min, 300 g), the cell pellet was resuspended in staining buffer (PBS
supplemented with 5% FBS). High-affinity Fc receptors were blocked by incubation with purified
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anti-mouse CD16/CD32 (BD Biosciences, Erembodegem, Belgium) for 15 min at 4 ◦C. Subsequently,
the cells were incubated with PerCP-Cy® 5.5 rat anti-mouse CD45 (BD Biosciences) diluted in staining
buffer and put on a rotary shaker for 45 min at room temperature for incubation. Following three
washing steps with 1 mL staining buffer, the cell pellet was resuspended in 500 µL flow buffer and
placed on ice until flow cytometry analysis. Subsequently cells were analyzed using a FACSCaliburTM
flow cytometer (BD Biosciences, Erembodegem, Belgium). The fluorescence for the Cy® 5.5-label was
measured at 488/690 nm. Data analysis was performed using the FlowJo™ analysis software (Treestar,
Costa Mesa, CA, USA).
2.10. Statistical Analysis
All experiments were performed in technical triplicate and with≥ 2 independent biological repeats
(≥ n = 2), unless otherwise stated. All data are presented as mean ± standard deviation (SD). Statistical
analysis was performed via one way ANOVA, unless otherwise stated, followed by a Bonferroni
multiple comparison test, using GraphPad Prism software version 8.
3. Results and Discussion
3.1. Pulmonary Surfactant (PS) Potentiates siRNA Delivery in Non-Pulmonary Cell Lines
As mentioned above, earlier work has demonstrated improved siRNA delivery and targeted
gene silencing with PS-coated nanocomposites in both non-small cell lung cancer cells (H1299) and
alveolar macrophages [21,24,25]. Corroborating these results, as shown in Figure 2a, layering cationic
siNGs with a negatively charged PS bilayer (i.e., Curosurf®) strongly reduces cellular uptake in the
H1299 cell line. Importantly, despite the lower intracellular siRNA dose, the same level of targeted
gene knockdown is obtained (Figure 2b), indicating that the CS coat enhances the fraction of the
internalized siRNA dose that is delivered into the cytosol. A comparable outcome was obtained for
the murine alveolar macrophage cell line MH-S, targeting the CD45 gene (Figure 2c,d). To evaluate
if PS can likewise promote siRNA delivery in cell lines derived from other organs, human ovarian
carcinoma cells (SKOV-3) and human hepatoma cells (Huh-7) were treated with CS-coated siNGs
(Figure 2e–h). Consistent with earlier reports, the anionic CS outer layer significantly inhibited cellular
internalization of siNGs in both cell types. However, despite the ≥4-fold reduction in intracellular
siRNA dose, also in these cell lines a comparable knockdown of the targeted reporter genes relative
to the uncoated siNGs was observed, albeit that the Huh-7 reporter cell line in general appeared to
be more difficult to transfect. These data support the notion that although the lungs constitute the
natural habitat of lung surfactant, its beneficial effect on intracellular siRNA delivery is not limited to
lung-related cell types and that PS-inspired drug delivery should not be restricted to the lungs as main
target tissue.
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3.2. The Activity of SP-B Is Dependent on Its Lipid Microenvironment
In recent work, Merckx et al. revealed that surfactant protein B (SP-B) is a key component in lung
surfactant that dictates cellular siRNA delivery [25]. However, the activity of SP-B was proven to be
strongly dependent on the type of lipids with which it is combined, with the more fluid lipid mixture
DOPC:PG (85:15 wt%) clearly outperforming its more rigid counterpart DPPC:PG (85:15 wt%) in terms
of in vitro siRNA delivery efficiency. It is postulated that less resistance against lateral movement in a
less rigid proteolipid coat could promote SP-B-mediated intermembrane interactions [34,37]. To extend
our understanding, siNGs were coated with DSPC:PG (85:15 wt%) of which the main lipid has a
substantially higher phase transition temperature (Tc) of 55 ◦C, compared to DPPC (41 ◦C). The absence
of SP-B in the lipid coat inhibited siNG-mediated gene silencing, independent of the type of lipid
used. Supplementation of the DOPC:PG and DPPC:PG lipid coat with SP-B did result in reduced
eGFP expression levels, albeit that the improvement in gene silencing was statistically significant
solely for the more fluid DOPC-containing lipid bilayer (Figure 3a). Importantly, with DSPC as main
phospholipid, no gene silencing could be observed anymore. Of note, using an identical coating
protocol, the use of DSPC as main lipid component resulted in micrometer sized nanocomposites
(Table 1). These data altogether suggest that the Tc of the lipid coat influences both the colloidal stability
of the core-shell formulation as well as its intracellular siRNA delivery potential.
Table 1. Representative DLS data and ζ-potential of different formulations used in this study.
Sample Hydrodynamic Diameter (nm) Ð ζ -Potential (mV)
NGs DOPC:PG 168 ± 2 0.24 −23 ± 1
NGs DPPC:PG 257 ± 2 0.45 −20 ± 1
NGs DSPC:PG 5480 ± 2700 1 −16 ± 0
Dex-HEMA NGs 195 ± 3 0.18 17 ± 0
Dex-HEMA NGs LIP 160 ± 1 0.24 −29 ± 1
Dex-HEMA NGs LIP SP-B 158 ± 3 0.26 −35 ± 0
Dex-MA NGs 203 ± 1 0.26 15 ± 3
Dex-MA NGs LIP 117 ± 1 0.26 −35 ± 0
Dex-MA NGs LIP SP-B 114 ± 2 0.39 −40 ± 1
DOTAP:DOPE LPX 132 ± 3 0.40 56 ± 4
DOTAP:DOPE LPX SP-B 114 ± 2 0.38 48 ± 2
Nanogels (NGs); Dextran hydroxyethyl methacrylate (dex-HEMA); dextran methacrylate
(dex-MA); lipid coating DOPC:PG (LIP); Surfactant Protein B (SP-B); lipoplexes (LPX); polydispersity
(Ð). Samples were measured in HEPES buffer 20 mM pH 7.4.
Natural PS contains a substantial fraction of neutral lipids, mainly cholesterol (~8 wt%), which
modulate surfactant activity [38]. However, excessive cholesterol levels are known to interfere
with normal surfactant function, possibly contributing to respiratory insufficiency [39,40]. As the
manufacturing of Curosurf® involves depletion of neutral lipids, including cholesterol and cholesteryl
esters, the data shown in Figure 2 and in earlier reports seem to indicate that the presence of cholesterol
is not strictly required for the siRNA delivery-promoting effect of SP-B. However, state-of-the-art lipid
formulations often contain high fractions of cholesterol (up to 40 wt%) as a stabilizing component for
in vivo application. Therefore, we sought to probe the impact of cholesterol on SP-B mediated siRNA
delivery (Figure 4). While supplementation of the DOPC:eggPG lipid mixture with physiological
cholesterol levels did not negatively influence siRNA delivery efficiency, gene silencing efficiency was
slightly impaired when further increasing the cholesterol fraction to ~25 wt%. Overall, we conclude
that cholesterol levels exceeding the endogenous PS fractions by far, partially hamper SP-B’s beneficial
effect on siRNA delivery.
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Figure 3. Impact of lipid phase transition temperature on formation and delivery efficiency of
SP-B containing proteolipid-coated nanogels. (a) Evaluation of eGFP silencing in H1299_eGFP
cells by uncoated or (proteo)lipid-coated siNGs with different lipid mixtures, supplemented with
0.4 wt% SP-B. All experiments were performed with a fixed NG concentration (30 µg/mL) and siRNA
concentration (50 nM). The SP-B effect is strongly influenced by the type of lipid with which it is
combined, highlighting the importance of a fluid lipid membrane in the formulation of the core-shell
nanocomposites. (b) Chemical structures and phase transition temperatures (Tc) of the different PC
lipids tested. Statistical analysis was performed via an unpaired t-test. Data are represented as the
mean ± SD (n = 2) and statistical significance is indicated (**** p < 0.0001, ns = not significant).
While anionic phospholipids are generally present in rather low concentrations in mammalian
tissues, PS represents an exception with its PG content of 7–12% by mass [41]. As mentioned above,
SP-B is a cationic amphipathic protein, of which the positive charges are believed to interact with
the head groups of anionic phospholipid species like PG. As previously reported, this interaction
could orchestrate the distribution of SP-B in the more disordered phases of PS membranes [42,43]. It is
conceivable that SP-B likewise connects electrostatically with the PG fraction in the nanocomposite
proteolipid coat, mimicking the natural interaction of SP-B with lipid bilayers. However, PG does not
constitute the only negative phospholipid in PS, where phosphatidylinositol (PI) and phosphatidylserine
(PhS) also play a role. Of note, PI represent the main negative phospholipid in lung surfactant of
other species, while in humans only fetal surfactant shows higher PI content relative to PG, which is
reversed with ageing [41]. The less abundant PhS seems to be mainly involved in surfactant metabolism
processes, although its exact role is still unclear [41]. Here, we aimed to evaluate the compatibility of
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SP-B with other anionic lipids by replacing the PG fraction with PhS or PI in the SP-B supplemented
DOPC:PG proteolipid coat of the nanocomposites (Figure 5). As expected, all coated formulations
substantially reduced the cellular uptake of the siNGs (>10-fold). PI containing nanocomposites
reached the highest knockdown levels, which could in part be explained by the relatively higher
intracellular siRNA dose. Most importantly, independent of the type of anionic lipid, the presence of
SP-B in the lipid coat significantly promotes gene silencing efficiency, indicating that the nature of the
negative phospholipid is not critical for the cellular effect of SP-B (Figure 5).Ph rmaceutics 2019, 11, x 10 of 17 
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Figure 4. Impact of cholesterol on biological efficacy of proteolipid-coated nanogels. Evaluation of
(a) cellular uptake and (c) gene silencing potential in H1299_eGFP cells of siRNA-loaded nanogels
(siNGs) coated with lipid mixtures containing physiological cholesterol (CHOL) levels (2.5, 5 to 10 wt%).
Data show one representative (technical triplicate) of two independent experiments; formulations with
different siRNA concentrations showed the same trend (data not shown). Evaluation of (b) cellular
uptake and (d) gene silencing potential of siNGs coated with increased cholesterol fraction in the outer
layer (~25 wt%) (n = 3). Cholesterol exceeding physiological levels partially hinder SP-B promoted
siRNA delivery. All experiments were performed with a fixed NG concentration (30 µg/mL) and
siRNA concentration (50 nM). LIP = DOPC:PG (85:15); LIP SP-B = DOPC:PG (85:15) + SP-B 0.4 wt%;
LIP SP-B CHOL = DOPC:CHOL:PG (60:25:15) + SP-B 0.4 wt%. Data are represented as the mean
± SD and statistical significance is indicated (* p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 0.0001,
ns = not significant).
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Figure 5. Role of the anionic lipid in biological efficacy of proteolipid-coated nanogels. (a) Cellular
uptake and (b) gene silencing evaluate on H1299_eGFP cells via flow cyt metry. SiRNA-loaded
nanogels (siNGs) were coated with a mixture of DOPC:PG, DOPC:PhS or DOPC:PI (weight ratio
85:15). The presence of negatively charged lipids is required to allow the formation of the core-shell
structure via electrostatic inte actions. The replacement of the anionic ph hatidylglycerol (PG) with
phosphatidylserine (PhS) or phosphatidylinositol (PI) does not abrogate SP-B’s beneficial effect on
siRNA delivery. All experiments were performed with a fixed NG concentration (30 µg/mL) and siRNA
concentration (50 nM). St tistical analysis w s performed via an unpaire t-test. Data are represented
as the mean ± SD (n = 3) and statistical significance is indicated (* p < 0.05, ** p < 0.01, **** p < 0.0001,
ns = not significant).
3.3. Degradability of the Nanogel Core Does Not Influence SP-B Activity
To date, the effect of SP-B on siRNA delivery has only been demonstrated using PS-inspired
proteolipid nanocomposites with a biodegradable hydrogel core (Figure 1). To evaluate whether the
degradation of the core contributes to the activity of SP-B, the hydrolysable dex-HEMA NG core
was replaced by its stable dex-MA counterpart with comparable physicochemical characteristics
(Figure 6) [28–30]. In line with earlier data from our group [31,44], dex-MA siNGs show a slightly
reduced intrinsic siRNA delivery potential relative to dex-HEMA siNGs (due to the absence of the
hydrolysable carbonate ester in the crosslinks), albeit similar uptake levels are achieved (data not
shown). However, coating of the former with a SP-B proteolipid bilayer also strongly promoted siRNA
delivery and target gene knockdown, indicating that degradability of the core material is not essential
for SP-B’s activity (Figure 6a).
In addition, intentionally degrading the dex-HEMA NG core (4 h incubation at 37 ◦C) after
proteolipid coating but prior to transfection did not seem to affect the gene knockdown efficiency
(Figure 6b). These results indicate that an intact polymeric core material in the core-shell nanocomposites
is likewise not essential to the delivery-promoting effect of SP-B.
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Figure 6. Impact of dextran nanogel core structure on SP-B mediated siRNA delivery. (a) Gene silencing
potential of (proteolipid-coated) siRNA-loaded NGs (siNGs) constructed with the hydrolysable
dex-HEMA or the stable dex-MA. Both formulations were coated with a mixture of DOPC:PG
(85:15 wt%) here abbreviated as LIP, with or without SP-B. Although the stable dex-MA shows a less
pronounced eGFP knockdown, SP-B promotes siRNA delivery equal to the degradable dex-HEMA.
Data are a summary of two independent experiments. Data are represented as the mean ± SD (n = 2)
and statistical significance is indicated (** p < 0.01, *** p < 0.005, ns = not significant). (b) Gene silencing
of (proteo)lipid-coated dex-HEMA NGs with an intact or degraded NG core. All experiments were
performed with a fixed NG concentration (30 µg/mL) and siRNA concentration (5 nM). Data show
one representative graph of two independent experiments; formulations with increased SP-B fraction
showed the same trend (data not shown).
3.4. Integration of SP-B into Cationic Liposomes Does Not Enhance siRNA Delivery
To form a stable core-shell nanocomposite, electrostatic interaction of a negatively charged lipid
shell with the cationic NG core is required [19,24]. Here, the NG enables siRNA encapsulation in the
nanocomposite and at the same time serves as a solid support for the deposition of the surfactant
shell. However, as the integrity of the core material is not essential for SP-B’s effect on siRNA delivery,
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we aimed to evaluate the impact of SP-B supplementation in cationic liposomes in which the siRNA
complexation is directly achieved by the positively-charged lipids. To date, cationic lipid nanoparticles
(LNPs) remain the most advanced nanoformulation for siRNA delivery [45]. LNPs are typically
composed of a cationic lipid and one or more helper lipids, in which the cationic lipid is the dominant
component as it enables both electrostatic complexation of the oppositely charged RNA as well as
cellular delivery by facilitating cellular uptake and endosomal escape, albeit that the latter step in
general lacks efficiency for the majority of siRNA nanomedicines [46]. Increasing the cytosolic delivery
potential of such formulations could reduce the dose of both carrier and cargo, thus mitigating the
risk of off-target effects. Here, we aimed to exploit the amphiphilic properties of SP-B to reconstitute
SP-B in the bilayer of a commercially available cationic liposomal formulation (i.e., DOTAP:DOPE
50:50 mol%). To obtain the lipoplexes (LPX), the formed liposomes were incubated with siRNA
solutions to obtain a charge ratio equal to 8 [47]. Adding 1 wt% of SP-B to the lipid composition
seemed to slightly reduce both hydrodynamic diameter as well as surface charge (Table 1). Likewise,
also the cellular internalization in the H1299 cell model was decreased when SP-B was present in the
DOTAP:DOPE bilayer, albeit without reaching statistical significance. Most importantly, although
higher SP-B fractions were applied here, no beneficial effect on intracellular siRNA delivery and
resulting target gene silencing could be noted in the presence of SP-B (Figure 7). It is hypothesized that
the high intrinsic cationic charge density of the DOTAP:DOPE liposomes might obscure the more subtle
membrane destabilizing effects of the cationic amphiphilic SP-B protein. On the other hand, it cannot
be excluded that electrostatic repulsion between cationic lipids and positively-charged SP-B molecules
could result in a less optimal distribution of the protein to enable intracellular siRNA delivery. More
detailed experiments are required to fully elucidate the contrasting effects of SP-B when reconstituted
in DOTAP:DOPE cationic liposomes.
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4. Conclusions
Previous studies have identified the endogenous surfactant protein B (SP-B) as siRNA delivery
enhancer when reconstituted in lipid-coated nanogels (NGs). The mechanism of action of SP-B at
the alveolar air-liquid interface has been investigated in detail, providing essential knowledge of the
impact of the lipid microenvironment on SP-B’s activity and, consequently, on surfactant dynamics.
Contrarily, the way SP-B is able to promote intracellular delivery of siRNA and how this activity might
be influenced by the lipid environment has not yet been described in detail. Here, we evaluated the
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influence of the main constituents of SP-B proteolipid-coated NGs, namely the lipid composition of the
proteolipid coat and the degradability of the NG core, on the activity of SP-B. While the inner core
degradability did not seem to be essential for SP-B promoted siRNA delivery, we showed a crucial
role of the surrounding lipid membranes. Specifically, we described the importance of membrane
fluidity and appropriate cholesterol levels, in analogy with the physiological interactions between
SP-B and lipids occurring at the alveolar air-liquid interface. In addition, the adjuvant effect of SP-B on
cellular siRNA delivery was supported by different types of anionic lipid species in the proteolipid
coat. On the other hand, a formulation of commonly used DOTAP:DOPE cationic liposomes with SP-B
did not result in an improved gene silencing effect. Importantly, we also showed the SP-B promoted
siRNA delivery in other pulmonary cell lines, suggesting its suitability to boost siRNA delivery in
extrapulmonary tissues as well. Altogether, these results provide useful insights that will support
future rational design of lipid-based SP-B nanoplatforms for siRNA delivery.
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